MVMarco Volante

Marco Volante

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marco Volante has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Metastasis of lung carcinoma in a pheochromocytoma

    by Antonio Gigante, Erika Messina, Federica Massa, Marco Volante, Anna Pia, Massimo Terzolo

    Tumor-to-tumor metastasis (TTM) is an established but rare entity. Lung carcinoma metastasizes commonly to adrenal glands; however, metastases into an already existing adrenal gland tumor are a rare finding. A 78-year-old man was diagnosed with pheochromocytoma, and during the disease staging, lung involvement was revealed. Functional imaging with both 18F-fluorodeoxyglucose (18F-FDG) and 68Ga-DOTA-Tyr3-Octreotate (68Ga-DOTA-TATE) positron emission tomography (PET) was performed: 18FDG-PET showed mild uptake in both the adrenal and pulmonary lesions, whereas 68Ga-DOTA-TATE-PET revealed intense uptake confined to the adrenal mass. This discordant pattern suggested the presence of 2 biologically distinct lesions. The right adrenal gland was surgically removed, and histology and immunohistochemistry confirmed 2 components within the tumor: a pheochromocytoma that included a lung cancer metastasis. Histopathological confirmation of the pulmonary primary lesion was not available. This is the second published case of a TTM of lung carcinoma inside a pheochromocytoma. Tumor-to-tumor metastasis should be considered in pathological diagnosis.

  • Open Access

    Three-Tier Prognostic Stratification of Lung Carcinoids (NET G1-G2-G3) by Multivariable, Data-Driven Integration of Ki-67 and Mitotic Count

    by Giulia Orlando, Valentina Veronesi, Eleonora Duregon, Vanessa Zambelli, Francesco Leo, Elisa Carla Fontana, Enrico Ruffini, Luisella Righi, Giuseppe Pelosi, Marco Volante, et al.

    Pulmonary neuroendocrine tumors (NETs) include typical and atypical carcinoids, corresponding to low- and intermediate-grade malignancies. Integration of necrosis, mitotic count per 2 mm² (MC), and Ki-67 index, a desirable criterion in the current WHO scheme, may enable a classification framework beyond conventional histology. We used a clustering method for mixed-type data, including necrosis, MC and Ki-67 index, on a single-institution cohort of 358 typical and 125 atypical carcinoids with long-term follow-up. An external validation series of 259 additional carcinoids was used. A three-cluster solution was selected, yielding a tiered prognostic stratification model, that included NETG1 (383 cases; mean MC: 0.7; necrosis: 8.1% of cases; mean Ki-67 index: 2.5%), NETG2 (77 cases; mean MC 2.3; necrosis 27.3%; mean Ki-67: 11.4%), and NETG3 (23 cases; mean MC: 5.5; necrosis 60.9%; mean Ki-67: 25.1%). The model was independent of histological classification. Ki-67 index was the strongest discriminator, distinguishing NET G1 tumors with a Ki-67 index < 6% from NET G3 tumors (Ki-67 > 16%), while MC contributed to identifying a subset of NET G2 tumors. The selected cut-offs were derived through a statistical approach evaluating hundreds of decision-tree configurations, following a sequential algorithm from Ki-67 to MC, with 6–16% identified as the most informative Ki-67 range for intermediate stratification. Necrosis added no discriminative value, as it was closely correlated with the Ki-67 index and MC. This classification corresponded to a progressive worsening of overall survival and, more significantly, relapse-free survival, and it was transferable to the external cohort. In conclusion, based on routinely available pathological parameters, this model provides a practical and reproducible classification of resected pulmonary NETs, overcoming the traditional typical–atypical carcinoid dichotomy and is potentially applicable to biopsy material.


  • Lung carcinoids (lung neuroendocrine tumors): integrated classification, molecular biology, diagnosis, and multidisciplinary management

    by Anna Koumarianou, Jules Derks, Marina Tsoli, Marco Volante, Lynnette Fernandez-Cuesta, Vikas Prasad, Pier Luigi Filosso, Benjamin Gibert, Thomas Walter, Alice Durand

    This narrative review aims to provide a comprehensive synthesis of current knowledge and guidelines on lung carcinoids, emphasizing the multidimensional approach required for effective diagnosis and management. The manuscript will: (i) define and classify lung carcinoids in accordance with the latest WHO classification system, and emphasize the importance of molecular markers for precise subtyping; (ii) analyze epidemiological trends, discuss prevalence, incidence, and mortality rates, alongside key risk factors including genetic predispositions (MEN1) and precursor lesions such as diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH); (iii) investigate the etiology and carcinogenesis of lung carcinoids, including insights into the molecular hallmarks and pathways that underlie tumor development and progression; (iv) detail clinical presentations, distinguishing pulmonary symptoms from secretory syndromes (carcinoid syndrome and Cushing syndrome), supported by visual aids to elucidate symptom prevalence and implications; (v) present an integrated diagnostic approach, encompassing state-of-the-art imaging modalities (CT, magnetic resonance imaging [MRI], 68Ga-SSA-positron emission tomography [PET]-CT) and advanced molecular pathology techniques; (vi) outline evidence-based treatment strategies, addressing early-stage interventions, systemic therapies, locoregional therapies, and emerging modalities such as immunotherapy and agnostic approaches; (vii) explore the role of multidisciplinary management, highlighting the critical importance of tumor boards dedicated to lung carcinoids and provide a checklist of key items for comprehensive case discussion and decision-making; and (viii) conclude with future perspectives, identifying gaps in current knowledge and suggest directions for research to enhance diagnosis, treatment, and overall patient quality of life.


  • Open Access

    High Prevalence of Potential Molecular Therapeutic Targets in Poorly Differentiated Thyroid Carcinoma

    by Vanessa Zambelli, Giulia Orlando, Marta Fornaro, Giulia Vocino Trucco, Ida Rapa, Francesca Napoli, Susanna Cappia, Lorenzo Daniele, Simonetta Piana, Mauro Papotti, et al.

    Poorly differentiated thyroid carcinoma (PDTC) is a rare thyroid cancer with aggressive clinical course and peculiar clinical/pathological characteristics but lacking effective therapeutic options, when surgery is not curative. We aimed at the molecular characterization of PDTC with a specific focus on the identification of potential therapeutic targets. A series of PDTC cases was selected from a multi-institutional network. Fifty-nine samples underwent wide targeted DNA and RNA next-generation sequencing (NGS) testing and immunohistochemical analysis for mismatch repair (MMR) proteins. Gene fusion analysis was enriched by 25 additional samples. Prevalence of MMR protein loss was 11.9%. The most prevalent mutations were in NRAS (25%) and TP53 (25%), mutually exclusive. TERT promoter ( TERTp ) mutations were detected in 19.6% of cases (10/51). NRAS -mutated cases were enriched for mutations in genes belonging to the same pathway. TP53 -mutated samples lacked TERTp co-mutations, but were associated with mutations in PTEN and in genes related to MMR system and/or loss of MMR proteins. TERTp mutations were the most prevalent alterations (28%, 7/25) in a third group that lacked NRAS or TP53 mutations. Four cases harbored gene fusions, including two cases harboring the TBL1XR1::PIK3CA fusion that has never been reported in thyroid cancer, so far. In conclusion, PDTC may be genomically segregated in subgroups with specific molecular characteristics. Overall, targetable gene fusions have a prevalence of 9% (4/42). Moreover, 47% of cases are potential candidates for individualized target therapies since they harbor mutations in genes coding for potentially targetable molecules and/or have defects in the MMR system.


  • Sampling Procedure and Preparatory Techniques

    by Teresa Rago, Guido Fadda, Marco Volante, Pierpaolo Trimboli

  • Open Access

    Diagnosis and grading of adrenal cortical carcinoma

    by Giulia Vocino Trucco, Eleonora Duregon, Mauro Papotti, Marco Volante

    The 5th edition of the WHO classification of endocrine and neuroendocrine tumors represents a significant advancement in the diagnostic approach to adrenocortical carcinoma (ACC), integrating novel molecular insights with established histopathological criteria to enhance diagnostic accuracy and to refine prognostic assessment. This review outlines key histopathological features and diagnostic strategies for ACC, offering a practical framework for evaluation and grading in daily practice. The updated WHO classification reaffirms the central role of histopathology, employing multiparametric scoring systems that assess invasion, architectural and cytological features, mitotic activity, and necrosis. However, these parameters often pose interpretive challenges, and no single algorithm ensures complete sensitivity, specificity, or reproducibility. Therefore, combining diagnostic approaches is advisable, particularly in morphologically ambiguous cases. For tumor grading, the WHO employs a two-tiered system based on a mitotic count cut of 20 per 10 mm 2 , aiming to improve interinstitutional consistency. Immunohistochemistry remains essential for diagnostic confirmation and prognostic evaluation. Among available markers, SF1 is the most specific for adrenocortical origin, while Ki-67, mismatch repair proteins, p53, and β-catenin are useful for predicting patient outcomes or screening for hereditary predisposition. In this complex diagnostic setting, artificial intelligence holds potential to support ACC diagnostics. However, its application is limited by the rarity of the disease, histological variability, and the scarcity of large, well-annotated datasets necessary for algorithm development.


  • Open Access

    Differential expression profiles of immunoregulatory genes in anaplastic thyroid carcinomas with a coexistent papillary carcinoma component

    by Giulia Orlando, Francesca Napoli, Vanessa Zambelli, Francesca Maletta, Giulia Capella, Eleonora Duregon, Marco Volante, Mauro Papotti

    Limited data exist on the immunoregulatory mechanisms involv ed in thyroid cancer, particularly in aggressive forms. This study aimed at identifying the expression profiles of immune-related genes and miRNAs in anaplastic (ATC) and poorly differentiated thyroid carcinomas (PDTC) associated with papillary carcinoma (PTC) components. Immune-related genes were investigated using the nCounter® PanCancer Immune Profiling Panel in separate ATC and PTC components of 12 cases, and in PDTC component only of nine additional cases associated with PTC. Global miRNAs profiling was also analyzed separately in ATC and PTC components of 8 out of the 12 cases. Comparative analysis between ATC and matched PTC components revealed largely stable gene expression patterns, with only a few genes deregulated. Of these, five genes ( MAP3K1 , PRKCD , CYFIP2 , BLNK , and EPCAM ) were downregulated, while six ( RIPK2 , ITGB1 , CCL3L1 , ITGA5 , PLAUR , and TICAM2 ) were upregulated in ATC. Furthermore, 54 miRNAs were significantly upregulated in ATC, as compared to PTC components. One of the most regulated pathways was the MAPK signaling, with six of these deregulated miRNAs targeting the MAP3K1 gene. Comparing ATC and PDTC, over 200 genes were differentially expressed between PDTC and ATC samples, involving all major immune-related pathways, with a consistent downregulation in PDTC. In conclusion, ATC displays high levels of expression of immunoregulatory genes as compared to PDTC. Moreover, a subset of genes and miRNAs is significantly de-regulated along progression from PTC to ATC, suggesting their potential role as biomarkers and involvement in key functional mechanisms.


  • Open Access

    Figure S7 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer

    by Daniela Conticelli, Marco Volante, Filippo Pietrantonio, Claudia Orrù, Martina Olivero, Alessia Nottegar, Felice Borghi, Gian L. Baiocchi, Giovanni Crotti, Uberto Fumagalli Romario, et al.

    H‐score correlation between the pathologists for AREG, EREG, and HER3 biomarkers.

  • Open Access

    Figure S5 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer

    by Daniela Conticelli, Marco Volante, Filippo Pietrantonio, Claudia Orrù, Martina Olivero, Alessia Nottegar, Felice Borghi, Gian L. Baiocchi, Giovanni Crotti, Uberto Fumagalli Romario, et al.

    Evaluation of the expression of EGFR and HER2 in cetuximab sensitive vs resistant cells.

  • Open Access

    Figure S8 from AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer

    by Daniela Conticelli, Marco Volante, Filippo Pietrantonio, Claudia Orrù, Martina Olivero, Alessia Nottegar, Felice Borghi, Gian L. Baiocchi, Giovanni Crotti, Uberto Fumagalli Romario, et al.

    Overall survival according HER3 expression in the COG cohort.